Last reviewed · How we verify
Vonoprazan and Amoxicillin for 14 days
Vonoprazan inhibits gastric acid secretion by blocking the proton pump, while amoxicillin is a beta-lactam antibiotic that kills Helicobacter pylori bacteria.
Vonoprazan inhibits gastric acid secretion by blocking the proton pump, while amoxicillin is a beta-lactam antibiotic that kills Helicobacter pylori bacteria. Used for Helicobacter pylori eradication in peptic ulcer disease, H. pylori-associated gastritis.
At a glance
| Generic name | Vonoprazan and Amoxicillin for 14 days |
|---|---|
| Also known as | VADT-14 |
| Sponsor | The First Affiliated Hospital with Nanjing Medical University |
| Drug class | Proton pump inhibitor (vonoprazan) + beta-lactam antibiotic (amoxicillin) |
| Target | H+/K+-ATPase (vonoprazan); bacterial penicillin-binding proteins (amoxicillin) |
| Modality | Small molecule |
| Therapeutic area | Gastroenterology / Infectious Disease |
| Phase | FDA-approved |
Mechanism of action
This is a combination therapy for H. pylori eradication. Vonoprazan is a potassium-competitive acid blocker (P-CAB) that irreversibly inhibits the H+/K+-ATPase pump in gastric parietal cells, creating an acidic environment hostile to the bacteria while allowing amoxicillin to penetrate and act effectively. Amoxicillin disrupts bacterial cell wall synthesis by inhibiting penicillin-binding proteins, leading to bacterial death.
Approved indications
- Helicobacter pylori eradication in peptic ulcer disease
- H. pylori-associated gastritis
Common side effects
- Diarrhea
- Nausea
- Abdominal discomfort
- Headache
- Allergic reactions (amoxicillin)
Key clinical trials
- Efficacy and Safety of 14-Day Vonoprazan-Based Dual Therapy Versus Quadruple Therapy for Helicobacter Pylori Eradication: A Multicentre, Non-Inferiority Randomized Controlled Trial (NA)
- Banxiaxiexin Decoction Combined With Vonoprazan-Amoxicillin Dual Therapy in H. Pylori Eradication (PHASE3)
- Helicobacter Pylori Screening and Treatment in the At-risk South Florida Community- AIM 1 (PHASE4)
- Fourteen-Day Vonoprazan-Based Dual Therapy With Amoxicillin as First-Line Helicobacter Pylori Treatment in Comparison With Extended Sequential Therapy (PHASE4)
- 7-day High-Dose Vonoprazan-amoxicillin Dual Therapy Versus 14-day Vonoprazan-amoxicillin Dual Therapy for H. Pylori (NA)
- CURE-H. Pylori: A Trial on the Combination of Anti-Ulcerants and Levofloxacin-Based Therapy for Helicobacter Pylori Eradication (PHASE4)
- Efficacy and Safety of 7-day Triple Therapy Containing Amoxicillin and Tetracycline Versus 14-day Dual Therapy for Helicobacter Pylori Eradication
- Eradication of Helicobacter Pylori Improves Metabolic Syndrome Through Modulation of Gut Microbiota. (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |